Although we have made significant progress in recognizing that cardio-renal-metabolic diseases and risk factors are connected and need to be treated comprehensively, we still have a lot of work to do to close current gaps.
The Annual CMHC meeting is a great platform to not only keep up with these advances, but also to learn how to translate them directly to patient care.
This year, we are excited to introduce a special track focused on digital health and technology, which will overview digital health interventions and their practical applications.
Our FDA Update and Late Breaking Trials is an excellent summary of key advances and approvals in cardio-renal-metabolic medicine in 2023, and a preview of what’s to come.
Play Video about CMHC 2023 Annual
The rest of our key tracks will do a deep dive on these topics and provide key pearls for the management of complex cardio-renal-metabolic patients.
Through case presentations, panel discussions, Q & A sessions, and opportunities to directly interact with leading experts, this meeting is invaluable in helping multi-disciplinary clinicians keep abreast of this ever-expanding field. If you are a clinician across disciplines or simply interested in improving care for patients with cardio-renal-metabolic disease, we believe that this in an excellent opportunity for you to learn and share experiences with your colleagues.
Pre-Conference: The Role of Digital Health & Technology in Cardiometabolic Risk Reduction: Where We Are and Where Are We Going |
Keynote Address: Screening for Social Determinants of Cardiometabolic Health & Practice Implications |
Non-Statin Therapies for LDL-C Lowering: Making Sense of Recent Data and Recommendations |
Which Patients Should Get SGLT2is and GLP-1 RAs for cardiorenal risk reduction? Interpreting Guidelines and Clinical Trials to Patient Care |
FDA Updates and Late-Breaking Trials in Cardiometabolic Medicine in 2023 |
Debate and Discussion: Is it Time to Compare High-Intensity Pharmacotherapy to Surgery for the Management of Obesity? |
Where Are We With Respect to Glycemic Control in T2D? A 2023 Update |
The Continuum of Heart Failure |
Agenda
The Role of Digital Health & Technology in Cardiometabolic Risk Reduction: Where We Are and Where Are We Going | |
Opening Remarks Chair: Seth Martin, MD, MHS | |
Setting the Stage: What Digital Health Means for Clinicians and Patients
Patrick Dunn, PhD | |
Technology & Digital Health in Lifestyle and Obesity | |
Health and Care Apps for Lifestyle and Obesity: The Importance of Self-Monitoring Tiffany Powell-Wiley, MD, MPH | |
Continuous Glucose Monitoring: The New Frontier in Lifestyle Management?
Athena Philis-Tsimikas, MD | |
Changing Behavior Using Digital Health for Long Term Weight Management
Martin S. Hagger, PhD | |
Panel Discussion and Audience Q&A Moderator: Seth Martin, MD, MHS Panelists: Tiffany Powell-Wiley, MD, MPH; Athena Philis-Tsimikas, MD; Martin S. Hagger, PhD | |
Technology & Digital Health in Type 2 Diabetes | |
The Role of CGM in the Management of Type 2 Diabetes: Patient Selection & Important Pearls
Supported by Dexcom. Grazia Aleppo, MD, FACE, FACP | |
Insulin Delivery and Insulin Pumps in Patients with Type 2 Diabetes
Viral Shah, MD | |
Panel Discussion and Audience Q&A Moderator: Seth Martin, MD, MHS Panelists: Grazia Aleppo, MD, FACE, FACP; Viral Shah, MD | |
Technology & Digital Health in CVD & CVD Risk Reduction | |
Technology to Close Gaps in Hypertension Care Daichi Shimbo, MD | |
Advances in Digital Health for Arrhythmia Management
Mohamed B. Elshazly, MD, MBEE, FACC | |
Health Technologies for CVD Prevention Francoise Marvel, MD | |
Panel Discussion and Audience Q&A Moderator: Seth Martin, MD, MHS Panelists: Daichi Shimbo, MD; Mohamed B. Elshazly, MD, MBEE, FACC: Francoise Marvel, MD | |
Technology & Digital Health in Cardiometabolic Health: Discussions & Practical Strategies for Implementation | |
Discussions & Perspectives: What Role Does Technology and Digital Health Play in Addressing Disparities in Care? Moderator: Seth Martin, MD, MHS Panelists: Yvonne Commodore-Mensah, PhD, MHS, RN; Christie M. Ballantyne, MD | |
How Do Clinicians and Patients Better Use This Data: Challenges and Possible Solutions Moderator: Seth Martin, MD, MHS Panelists: Eric D. Peterson, MD, MPH; Francoise Marvel, MD | |
Opening Remarks & FDA Update and Late Breaking Trials Moderator: Christie M. Ballantyne, MD Presenters: Deepak L. Bhatt, MD; Robert H. Eckel, MD; Keith C. Ferdinand; Anne L. Peters, MD | |
Keynote Address Screening for Social Determinants of Cardiometabolic Health & Practice Implications A. Enrique Caballero, MD | |
Session I: Obesity & Lifestyle | |
Opening Remarks Robert H. Eckel, MD | |
Diving Deeper Into Exercise Regimens for Cardiometabolic Health Mercedes Carnethon, PhD; Jane Reusch, MD | |
Debate and Discussion: Is it Time to Compare High-Intensity Pharmacotherapy to Surgery for the Management of Obesity? Donna H. Ryan, MD; Christopher D. Still, DO | |
The Intersection of Sleep and Cardiometabolic Risk: Important Connections and Practice Implications Sirimon Reutrakul, MD | |
Challenging Obesity Cases & Panel Discussion Moderator: Robert H. Eckel, MD Panelists: Mercedes Carnethon, PhD; Jane Reusch, MD; Donna H. Ryan, MD; Sirimon Reutrakul, MD; Christopher D. Still, DO | |
Session II: Dyslipidemia/Atherosclerosis/Thrombosis | |
|---|---|
Opening Remarks Christie M. Ballantyne, MD | |
Colchicine for Chronic Atherosclerosis as an Adjunct to Statin Therapy
Paul Ridker, MD | |
Statin Intolerance: How To Assess and Practical Pearls for Addressing It
Erin D. Michos, MD, MHS, FACC, FAHA, FASE, FASPC | |
Hypertriglyceridemia: Trials, Tribulations, and Transition to Clinical Practice Michael D. Shapiro, DO | |
Challenging Lipid Management Cases & Panel Discussion
Moderator: Christie M. Ballantyne, MD Panelists: Robert H. Eckel, MD, Erin D. Michos, MD, MHS, FACC, FAHA, FASE, FASPC; Patrick M. Moriarty, MD, FACP, FACC, FNLA, FESC; Pamela B. Morris, MD; Paul Ridker, MD; Michael D. Shapiro, DO | |
Session III: Diabetes | |
Opening Remarks Anne L. Peters, MD | |
Where Are We With Respect to Glycemic Control in T2D? A 2023 Update
Vanita R. Aroda, MD | |
Early Treatment Intensification in Type 2 Diabetes
Juan P. Frias, MD | |
Heterogeneity of Diabetes & Panel Discussion
Anne L. Peters, MD | |
Optimizing Glycemic Control With Commonly-Available Combination Therapies: Tips and Pearls Athena Philis-Tsimikas, MD | |
How Social Determinants of Health Impact Type 2 Diabetes Treatment Shivani Agarwal, MD, MPH | |
Challenging Diabetes Management Cases & Panel Discussion Moderator: Anne L. Peters, MD Panelists: Shivani Agarwal, MD, MPH; Vanita R. Aroda, MD; Juan P. Frias, MD; Athena Philis-Tsimikas, MD | |
Opening Remarks Keith C. Ferdinand, MD | |
Tackling the Disproportionate Burden of Resistant Hypertension in Black Adults: Perspectives & Advances
Keith C. Ferdinand, MD; Debbie Cohen, MD | |
Sleep and Hypertension: A Two-Way Street
Virend K. Somers, MD, PhD | |
The Role of Steroidal and Non-steroidal MRAs in Cardiorenal Risk Reduction
Ajay K. Singh, MBBS, FRCP, MBA | |
Which Patients Should Get SGLT2is and GLP-1 RAs for cardiorenal risk reduction? Interpreting Guidelines and Clinical Trials to Patient Care Pam R. Taub, MD, FACC, FASPC | |
The Continuum of Heart Failure
Alanna A. Morris MD, MSc, FHFSA, FACC, FAHA | |
Challenging Cardiorenal Cases & Expert Panel Discussion
Moderator: Keith C. Ferdinand, MD Panelists: Debbie Cohen, MD; Alanna Morris MD, MSc, FHFSA, FACC, FAHA; Ajay K. Singh, MBBS, FRCP, MBA; Virend K. Somers, MD, PhD; Pam R. Taub, MD, FACC, FASPC | |
